Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction

Diseases of the Esophagus

Volumn 29, Issue 5, 2016, Pages 442-447

  Sunde, B ^a,b   Ericson, J ^a,b   Kumagai, K ^b   Lundell, L ^a,b   Tsai, J A ^a,b   Lindblad, M ^a,b   Rouvelas, I ^a,b   Friesland, S ^a,b   Wang, N ^b   Nilsson, M ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

appetite scoring; dysphagia; esophageal cancer; neoadjuvant therapy; Watson scale

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DYSPHAGIA; EDMONTON ASSESSMENT SYSTEM VISUAL ANALOG SCALE APPETITE QUESTIONNAIRE; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL JUNCTION; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUTRITIONAL SUPPORT; OGILVIE SCORE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WATSON SCALE;

EID: 84978818614     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12352     Document Type: Article

References (29)

1. Mariette C, Piessen G, Triboulet J P. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8: 545–553.
2. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005; 6: 864–870.
3. Regional Cancer Center Sweden. Swedish National quality report Esophageal-and Gastric Cancer 2013, 2014.
4. Nagaraja V, Cox M R, Eslick G D. Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol 2014; 5: 119–126.
5. Siddiqui A A, Glynn C, Loren D, Kowalski T. Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study. Dis Esophagus 2009; 22: 216–222.
6. Siddiqui A A, Sarkar A, Beltz S et al. Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy. Gastrointest Endosc 2012; 76: 44–51.
7. Mariette C, Gronnier C, Duhamel A et al. Self-expanding covered metallic stent as a bridge to surgery in esophageal cancer: impact on oncologic outcomes. J Am Coll Surg 2015; 220 (3): 287–296.
8. Tan C J, Dasari B V, Gardiner K. Systematic review and meta-analysis of randomized clinical trials of self-expanding metallic stents as a bridge to surgery versus emergency surgery for malignant left-sided large bowel obstruction. Br J Surg 2012; 99: 469–476.
9. van Hooft J E, Bemelman W A, Oldenburg B et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol 2011; 12: 344–352.
10. Sinapi I, Navez B, Hamoir M et al. Seeding of the percutaneous endoscopic gastrostomy site from head and neck carcinoma: case report and review of the literature. Head Neck 2013; 35: E209–212.
11. Mariette C, De Botton M L, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol 2012; 19: 2128–2134.
12. Touchefeu Y, Archambeaud I, Landi B et al. Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. Dig Liver Dis 2014; 46: 283–286.
13. Dakkak M, Bennett J R. A new dysphagia score with objective validation. J Clin Gastroenterol 1992; 14: 99–100.
14. Watson D I, Pike G K, Baigrie R J et al. Prospective double-blind randomized trial of laparoscopic Nissen fundoplication with division and without division of short gastric vessels. Ann Surg 1997; 226: 642–652.
15. Ogilvie A L, Dronfield M W, Ferguson R, Atkinson M. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 1982; 23: 1060–1067.
16. Brurera E M M, Selmser P, Macmillian K. The Edmonton Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 6–9.
17. Chirieac L R, Swisher S G, Ajani J A et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347–1355.
18. Mandard A M, Dalibard F, Mandard J C et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686.
19. Di Fiore F, Lecleire S, Pop D et al. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007; 102: 2557–2563.
20. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 2013; 63: 232–248.
21. Pellen M G, Sabri S, Razack A, Gilani S Q, Jain P K. Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. Dis Esophagus 2012; 25: 48–53.
22. van Hagen P, Hulshof M C, van Lanschot J J et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
23. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925–930.
24. Mariette C, Dahan L, Mornex F et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416–2422.
25. Ribi K, Koeberle D, Schuller J C et al. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer 2009; 17: 1109–1116.
26. Avery K N, Metcalfe C, Barham C P, Alderson D, Falk S J, Blazeby J M. Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg 2007; 94: 1369–1376.
27. Blazeby J M, Sanford E, Falk S J, Alderson D, Donovan J L. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2005; 103: 1791–1799.
28. Bachmann R, Bachmann J, Hungbauer A et al. Impact of response evaluation for resectable esophageal adenocarcinoma – a retrospective cohort study. Int J Surg 2014; 12: 1025–1030.
29. Stahl M, Walz M K, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851–856.